Vaccines: Spinning molecular immunology into successful immunotherapy
暂无分享,去创建一个
[1] G. Klein,et al. Epstein–Barr Virus in Burkitt's Lymphoma and Nasopharyngeal Carcinoma: EBV DNA in Biopsies of Burkitt Tumours and Anaplastic Carcinomas of the Nasopharynx , 1970, Nature.
[2] C. Mckhann,et al. ANTIGENIC SPECIFICITIES ON MURINE SARCOMA CELLS , 1971, The Journal of experimental medicine.
[3] W. Szmuness. Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. , 1978, Progress in medical virology. Fortschritte der medizinischen Virusforschung. Progres en virologie medicale.
[4] D. Shafritz,et al. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. , 1981, The New England journal of medicine.
[5] Lu-Yu Hwang,et al. HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS A Prospective Study of 22 707 Men in Taiwan , 1981, The Lancet.
[6] W. Bodmer,et al. Lack of expression of HLA-ABC antigens in choriocarcinoma and other human tumor cell lines. , 1982, National Cancer Institute monograph.
[7] C. Bréchot. [What is the role of hepatitis B virus in the appearance of hepatocellular carcinomas in patients with alcoholic cirrhosis?]. , 1982, Gastroenterologie clinique et biologique.
[8] S. Davis,et al. Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[9] B. Moss,et al. Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[10] F. Grosveld,et al. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation , 1984, Nature.
[11] K. Münger,et al. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. , 1989, The EMBO journal.
[12] R. Warnke,et al. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. , 1989, The New England journal of medicine.
[13] T. Wu,et al. Detection of ebv gene expression in reed‐sternberg cells of Hodgkin's disease , 1990, International journal of cancer.
[14] Arnold J. Levine,et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.
[15] H. Koeppen,et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[16] D. Galloway,et al. Characterization of the humoral immune response to genital papillomaviruses. , 1990, Molecular biology & medicine.
[17] R. Steinman,et al. The dendritic cell system and its role in immunogenicity. , 1991, Annual review of immunology.
[18] P. Chomez,et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.
[19] P. Linsley,et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.
[20] J. Banchereau,et al. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells , 1992, Nature.
[21] A. Harris,et al. Loss of HLA class‐I alleles, heavy chains and β2‐microglobulin in colorectal cancer , 1992, International journal of cancer.
[22] M. Perkus,et al. Highly attenuated poxvirus vectors. , 1992, AIDS research and human retroviruses.
[23] R. Steinman,et al. Identification of proliferating dendritic cell precursors in mouse blood , 1992, The Journal of experimental medicine.
[24] J. Yewdell,et al. Identification of human cancers deficient in antigen processing , 1993, The Journal of experimental medicine.
[25] J. Allison,et al. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.
[26] R. Levy,et al. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma , 1993, Nature.
[27] E. Jaffee,et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[28] E. Thorsby,et al. p21‐ras‐peptide‐specific T‐cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly → Asp) , 2007, International journal of cancer.
[29] J. Banchereau,et al. Activation of human dendritic cells through CD40 cross-linking , 1994, The Journal of experimental medicine.
[30] P. Srivastava,et al. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. , 1994, Journal of immunology.
[31] E. Thorsby,et al. A K‐ras 13GLY → ASP mutation is recognized by HLA‐DQ7 restricted T cells in a patient with colorectal cancer. Modifying effect of DQ7 on established cancers harbouring this mutation? , 1994, International journal of cancer.
[32] F. Sallusto,et al. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.
[33] L. Zitvogel,et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.
[34] M. Davis,et al. T-cell recognition of antigen. A process controlled by transient intermolecular interactions. , 1995, Annals of the New York Academy of Sciences.
[35] E. Gilboa,et al. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes , 1995, The Journal of experimental medicine.
[36] Kathleen R. Cho,et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[37] D. Pardoll,et al. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours , 1995, Nature Medicine.
[38] M. Pfreundschuh,et al. Human neoplasms elicit multiple specific immune responses in the autologous host. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[39] P. Srivastava,et al. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. , 1995, Science.
[40] M. Serrano,et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.
[41] E. Paoletti,et al. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC. , 1995, Developments in biological standardization.
[42] H. Rammensee,et al. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96 , 1995, The Journal of experimental medicine.
[43] J. Sadoff,et al. Attenuated Shigella as a DNA Delivery Vehicle for DNA-Mediated Immunization , 1995, Science.
[44] Mark M. Davis,et al. T‐Cell Recognition of Antigen , 1995 .
[45] A Sette,et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. , 1996, Journal of immunology.
[46] Michael D. Roth,et al. Human CD14+ leukocytes acquire the phenotype and function of antigen‐presenting dendritic cells when cultured in GM‐CSF and IL‐4 , 1996, Journal of leukocyte biology.
[47] R. Steinman,et al. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. , 1996, Journal of immunological methods.
[48] E. Gilboa,et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo , 1996, The Journal of experimental medicine.
[49] E. Maraskovsky,et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified , 1996, The Journal of experimental medicine.
[50] P. Robbins,et al. Human tumor antigens recognized by T cells. , 1996, Current opinion in immunology.
[51] B. Moss. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[52] A. Lanzavecchia,et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation , 1996, The Journal of experimental medicine.
[53] F. Guarnieri,et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.
[54] D. Pardoll,et al. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? , 1996, The Journal of experimental medicine.
[55] S. Rosenberg,et al. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[56] M. Colombo,et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo , 1996, The Journal of experimental medicine.
[57] B. Bogen. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma , 1996, European journal of immunology.
[58] H. Young,et al. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[59] Edgar G. Engleman,et al. Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.
[60] G. Schuler,et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. , 1997, Advances in experimental medicine and biology.
[61] B. Moss,et al. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. , 1997, Vaccine.
[62] F. Marshall,et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. , 1997, Cancer research.
[63] Özlem Türeci,et al. SSX: A multigene family with several members transcribed in normal testis and human cancer , 1997, International journal of cancer.
[64] J. Berzofsky,et al. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. , 1997, Journal of immunology.
[65] Antonio Lanzavecchia,et al. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells , 1997, Nature.
[66] J. Bluestone,et al. Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy , 1997, The Journal of experimental medicine.
[67] D. Kufe,et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells , 1997, Nature Medicine.
[68] S. Rosenberg,et al. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. , 1997, Journal of the National Cancer Institute.
[69] L. Old,et al. Cancer Tumor antigens. , 1997, Current opinion in immunology.
[70] S. Rafii,et al. Dendritic Cells Genetically Modified with an Adenovirus Vector Encoding the cDNA for a Model Antigen Induce Protective and Therapeutic Antitumor Immunity , 1997, The Journal of experimental medicine.
[71] P. Srivastava,et al. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. , 1997, Science.
[72] A. Chalian,et al. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes , 1997, Nature Biotechnology.
[73] Lieping Chen,et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors , 1997, Nature Medicine.
[74] D. Hanahan,et al. Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy , 1997, The Journal of experimental medicine.
[75] S. Rosenberg,et al. Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases , 1997, The Journal of experimental medicine.
[76] N. Bhardwaj,et al. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. , 1997, Blood.
[77] K. Timmis,et al. Oral Somatic Transgene Vaccination Using Attenuated S. typhimurium , 1997, Cell.
[78] R. Young,et al. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[79] R. Steinman,et al. Developmental regulation of MHC class II transport in mouse dendritic cells , 1997, Nature.
[80] J. Brady,et al. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction , 1998, Nature.
[81] T. Blankenstein,et al. B cells inhibit induction of T cell-dependent tumor immunity , 1998, Nature Medicine.
[82] R. Steinman,et al. Dendritic cells and the control of immunity , 1998, Nature.
[83] C. Lowenstein,et al. The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.
[84] Jonathan J. Lewis,et al. Heteroclitic Immunization Induces Tumor Immunity , 1998, The Journal of experimental medicine.
[85] D. Pardoll,et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[86] Dirk Schadendorf,et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.
[87] H. Youn,et al. Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes. , 1998, Immunity.
[88] J. Becker,et al. Immunocytokines: a promising approach to cancer immunotherapy. , 1998, Pharmacology & therapeutics.
[89] J. Allison,et al. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[90] D. Neuberg,et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[91] G. Zhu,et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.
[92] M. Colombo,et al. Dendritic Cells Infiltrating Tumors Cotransduced with Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf) and Cd40 Ligand Genes Take up and Present Endogenous Tumor-Associated Antigens, and Prime Naive Mice for a Cytotoxic T Lymphocyte Response , 1999, The Journal of experimental medicine.
[93] R. Fisher,et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] R. Kurman,et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. , 1999, Human gene therapy.
[95] A. Chalian,et al. CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo. , 1999, Journal of immunology.
[96] B. Moss,et al. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[97] D. Spriggs,et al. Bacterial mucosal vaccines: Vibrio cholerae as a live attenuated vaccine/vector paradigm. , 1999, Current topics in microbiology and immunology.
[98] J. Allison,et al. Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.
[99] P. Pouwels,et al. Live bacterial delivery systems for development of mucosal vaccines. , 2000, Current opinion in molecular therapeutics.
[100] G. Alvord,et al. Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity1 , 2000, The Journal of Immunology.
[101] G. Lewis,et al. Recent advances with recombinant bacterial vaccine , 2000 .
[102] R. Steinman,et al. The Dendritic Cell Receptor for Endocytosis, Dec-205, Can Recycle and Enhance Antigen Presentation via Major Histocompatibility Complex Class II–Positive Lysosomal Compartments , 2000, The Journal of cell biology.
[103] G. Freeman,et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.
[104] T. Wu,et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. , 2000, Cancer research.
[105] M. Tremblay,et al. The T-cell protein tyrosine phosphatase. , 2000, Seminars in immunology.
[106] E. Jaffee,et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. , 2000, Immunity.
[107] G. Lewis,et al. Recent advances with recombinant bacterial vaccine vectors. , 2000, Molecular medicine today.
[108] Stuart K. Calderwood,et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine , 2000, Nature Medicine.
[109] H. Nishina,et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b , 2000, Nature.
[110] J. Rothman,et al. Receptor-Mediated Uptake of Antigen/Heat Shock Protein Complexes Results in Major Histocompatibility Complex Class I Antigen Presentation via Two Distinct Processing Pathways , 2000, The Journal of experimental medicine.
[111] B. Foster,et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. , 2000, Cancer research.
[112] E. Shevach,et al. Cbl-b regulates the CD28 dependence of T-cell activation , 2000, Nature.
[113] C. Klein,et al. Comparative Analysis of Genetically Modified Dendritic Cells and Tumor Cells as Therapeutic Cancer Vaccines , 2000, The Journal of experimental medicine.
[114] A. Ramsay,et al. The prime-boost strategy: exciting prospects for improved vaccination. , 2000, Immunology today.
[115] M. Peshwa,et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] R. Barth,et al. Equipotent Generation of Protective Antitumor Immunity by Various Methods of Dendritic Cell Loading With Whole Cell Tumor Antigens , 2001, Journal of immunotherapy.
[117] Josef M. Penninger,et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling , 2001, Nature.
[118] H. Ploegh,et al. Virus subversion of immunity: a structural perspective. , 2001, Current opinion in immunology.
[119] S. Chen,et al. Targeting dendritic cells to enhance DNA vaccine potency. , 2001, Cancer research.
[120] T. Wu,et al. Improving Vaccine Potency Through Intercellular Spreading and Enhanced MHC Class I Presentation of Antigen1 , 2001, The Journal of Immunology.
[121] P. Srivastava,et al. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. , 2001, Immunity.
[122] D. Pardoll,et al. B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells , 2001, The Journal of experimental medicine.
[123] J. Mulé,et al. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. , 2001, Cancer research.
[124] T. Ratliff,et al. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (alvac) cytokine gene delivery induces destruction of established prostate tumors , 2001, International journal of cancer.
[125] J. Egen,et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. , 2001, Annual review of immunology.
[126] R. Issels,et al. The role of heat shock protein (hsp70) in dendritic cell maturation: Hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors , 2001, European journal of immunology.
[127] C. Lowenstein,et al. Intersection of interferon and hypoxia signal transduction pathways in nitric oxide-induced tumor apoptosis. , 2001, Cancer research.
[128] L. Grochow,et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[129] T. Wu,et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. , 2001, Cancer research.
[130] Larry R. Smith,et al. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. , 2001, Cancer research.
[131] S. Akira,et al. Toll-like receptors: critical proteins linking innate and acquired immunity , 2001, Nature Immunology.
[132] C Crimi,et al. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. , 2001, Vaccine.
[133] E. Repasky,et al. Characterization of Heat Shock Protein 110 and Glucose-Regulated Protein 170 as Cancer Vaccines and the Effect of Fever-Range Hyperthermia on Vaccine Activity1 , 2001, The Journal of Immunology.
[134] M. Sadelain,et al. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. , 2001, Blood.
[135] Tomas Mustelin,et al. Activation of the Cooh-Terminal Src Kinase (Csk) by Camp-Dependent Protein Kinase Inhibits Signaling through the T Cell Receptor , 2001, The Journal of experimental medicine.
[136] G. Freeman,et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.
[137] D. Hilton,et al. Negative regulation of cytokine signaling , 2001, Journal of leukocyte biology.
[138] N. Ohara,et al. Recombinant BCG vaccines. , 2001, Vaccine.
[139] M. Croft,et al. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance , 2001, Nature Medicine.
[140] P. Srivastava. Roles of heat-shock proteins in innate and adaptive immunity , 2002, Nature Reviews Immunology.